146 related articles for article (PubMed ID: 33707553)
1. A new bioinformatics approach identifies overexpression of GRB2 as a poor prognostic biomarker for prostate cancer.
Iwata T; Sedukhina AS; Kubota M; Oonuma S; Maeda I; Yoshiike M; Usuba W; Minagawa K; Hames E; Meguro R; Cho S; Chien SHH; Urabe S; Pae S; Palanisamy K; Kumai T; Yudo K; Kikuchi E; Sato K
Sci Rep; 2021 Mar; 11(1):5696. PubMed ID: 33707553
[TBL] [Abstract][Full Text] [Related]
2. Where is the limit of prostate cancer biomarker research? Systematic investigation of potential prognostic and diagnostic biomarkers.
Kremer A; Kremer T; Kristiansen G; Tolkach Y
BMC Urol; 2019 Jun; 19(1):46. PubMed ID: 31170942
[TBL] [Abstract][Full Text] [Related]
3. Random forest-based modelling to detect biomarkers for prostate cancer progression.
Toth R; Schiffmann H; Hube-Magg C; Büscheck F; Höflmayer D; Weidemann S; Lebok P; Fraune C; Minner S; Schlomm T; Sauter G; Plass C; Assenov Y; Simon R; Meiners J; Gerhäuser C
Clin Epigenetics; 2019 Oct; 11(1):148. PubMed ID: 31640781
[TBL] [Abstract][Full Text] [Related]
4. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
[TBL] [Abstract][Full Text] [Related]
5. Development and Validation of an Individualized Immune Prognostic Signature for Recurrent Prostate Cancer.
Jin Y; Wang L; Lou H; Song C; He X; Ding M
Comb Chem High Throughput Screen; 2021; 24(1):98-108. PubMed ID: 32593277
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of GRB2 is correlated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma.
Li LY; Li EM; Wu ZY; Cao HH; Shen JH; Xu XE; Chen B; Wu JY; Xu LY
Int J Clin Exp Pathol; 2014; 7(6):3132-40. PubMed ID: 25031732
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of SLC6A1 associates with drug resistance and poor prognosis in prostate cancer.
Chen C; Cai Z; Zhuo Y; Xi M; Lin Z; Jiang F; Liu Z; Wan Y; Zheng Y; Li J; Zhou X; Zhu J; Zhong W
BMC Cancer; 2020 Apr; 20(1):289. PubMed ID: 32252682
[TBL] [Abstract][Full Text] [Related]
8. Identification of GRB2 and GAB1 coexpression as an unfavorable prognostic factor for hepatocellular carcinoma by a combination of expression profile and network analysis.
Zhang Y; Li Z; Yang M; Wang D; Yu L; Guo C; Guo X; Lin N
PLoS One; 2013; 8(12):e85170. PubMed ID: 24391994
[TBL] [Abstract][Full Text] [Related]
9. High BIRC7 Expression Might Be an Independent Prognostic Indicator of Poor Recurrence-Free Survival in Patients With Prostate Cancer.
Yang Y; Sun P; Xu W; Xia W
Technol Cancer Res Treat; 2018 Jan; 17():1533033818809694. PubMed ID: 30376767
[TBL] [Abstract][Full Text] [Related]
10. Interrogation of ERG gene rearrangements in prostate cancer identifies a prognostic 10-gene signature with relevant implication to patients' clinical outcome.
Bismar TA; Alshalalfa M; Petersen LF; Teng LH; Gerke T; Bakkar A; Al-Mami A; Liu S; Dolph M; Mucci LA; Alhajj R
BJU Int; 2014 Feb; 113(2):309-19. PubMed ID: 24006850
[TBL] [Abstract][Full Text] [Related]
11. Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression.
Peng S; Du T; Wu W; Chen X; Lai Y; Zhu D; Wang Q; Ma X; Lin C; Li Z; Guo Z; Huang H
Urol Oncol; 2018 Aug; 36(8):366.e1-366.e9. PubMed ID: 29903461
[TBL] [Abstract][Full Text] [Related]
12. CPNE1 Is a Useful Prognostic Marker and Is Associated with TNF Receptor-Associated Factor 2 (TRAF2) Expression in Prostate Cancer.
Liang J; Zhang J; Ruan J; Mi Y; Hu Q; Wang Z; Wei B
Med Sci Monit; 2017 Nov; 23():5504-5514. PubMed ID: 29151113
[TBL] [Abstract][Full Text] [Related]
13. Identification of UBE2C as hub gene in driving prostate cancer by integrated bioinformatics analysis.
Wang Y; Wang J; Tang Q; Ren G
PLoS One; 2021; 16(2):e0247827. PubMed ID: 33630978
[TBL] [Abstract][Full Text] [Related]
14. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW
Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899
[TBL] [Abstract][Full Text] [Related]
15. GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.
Jeyapala R; Savio AJ; Olkhov-Mitsel E; Kamdar S; Zhao F; Cuizon C; Liu RSC; Zlotta A; Fleshner N; van der Kwast T; Bapat B
Eur Urol Oncol; 2019 May; 2(3):231-238. PubMed ID: 31200836
[TBL] [Abstract][Full Text] [Related]
16. Identification of prognosis biomarkers of prostatic cancer in a cohort of 498 patients from TCGA.
Chen Z; Hu H
Curr Probl Cancer; 2019 Dec; 43(6):100503. PubMed ID: 31563279
[TBL] [Abstract][Full Text] [Related]
17. Identification of potential prognostic biomarkers for breast cancer using WGCNA and PPI integrated techniques.
Zheng G; Zhang C; Zhong C
Ann Diagn Pathol; 2021 Feb; 50():151675. PubMed ID: 33291061
[TBL] [Abstract][Full Text] [Related]
18. Golgi Phosphoprotein-3 and Y-Box-Binding Protein-1 Are Novel Markers Correlating With Poor Prognosis in Prostate Cancer.
Abd El-Maqsoud NM; Osman NA; Abd El-Hamid AM; Fath El-Bab TK; Galal EM
Clin Genitourin Cancer; 2016 Apr; 14(2):e143-52. PubMed ID: 26794392
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.
Xu S; Yi XM; Zhou WQ; Cheng W; Ge JP; Zhang ZY
Int J Clin Exp Pathol; 2015; 8(11):14335-44. PubMed ID: 26823749
[TBL] [Abstract][Full Text] [Related]
20.
Rezk M; Chandra A; Addis D; Møller H; Youssef M; Dasgupta P; Yamamoto H
BMJ Open; 2019 Mar; 9(3):e025161. PubMed ID: 30852544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]